- 全部删除
- 您的购物车当前为空
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。
为众多的药物研发团队赋能,
让新药发现更简单!
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 987 | In stock | |
5 mg | ¥ 2,350 | In stock | |
10 mg | ¥ 3,260 | In stock | |
25 mg | ¥ 4,700 | In stock | |
50 mg | ¥ 6,380 | In stock | |
100 mg | ¥ 8,590 | In stock | |
200 mg | ¥ 11,600 | In stock |
AGI-14100 相关产品
产品描述 | AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
靶点活性 | HT1080 (chondrosarcoma cell lines):1 nM, IDH1-R132H homodimer (mutation):6 nM |
体内活性 | AGI-14100 (50 mg/kg; oral; single; female nude BALB/c mice) inhibition robust tumor 2-HG was achieved 12 hours post-dose demonstrating desirable in vivo results.[1] AGI-14100 had decent oral pharmacokinetics (PK) properties in rats (F =44 %), dogs (F =18 %), and cynomolgus monkeys (F =43 %).[1] |
别名 | AGI 14100 |
分子量 | 599.96 |
分子式 | C29H22ClF4N5O3 |
CAS No. | 1448346-43-7 |
Smiles | N([C@H](C(NC1CC(F)(F)C1)=O)C2=C(Cl)C=CC=C2)(C(=O)[C@H]3N(C(=O)CC3)C4=CC(C#N)=CC=N4)C5=CC(F)=CC(F)=C5 |
密度 | 1.51 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (83.34 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容